TMEM42: A Transmembrane Protein Target for Drug Development and Cancer Treatment

Target Name: TMEM42

NCBI ID: G131616

TMEM42

Other Name(s): transmembrane protein 42 | TMM42_HUMAN | Transmembrane protein 42

TMEM42: A Transmembrane Protein Target for Drug Development and Cancer Treatment

TMEM42 (Transmembrane Protein 42) is a 21-kDa protein that is expressed in various cell types, including neurons, muscle cells, and epithelial cells. Its primary function is to regulate the intracellular signaling pathway known as the TGF-β pathway, which plays a crucial role in cell growth, differentiation, and survival. TMEM42 has been identified as a potential drug target and biomarker for various diseases, including cancer.

Drug Target Potential

TMEM42 has been selected as a drug target due to its unique mechanism of action and its involvement in various cellular processes. The TGF-β pathway is a well-established target for drug development due to its involvement in the regulation of cell growth, angiogenesis, and cancer progression. Activation of the TGF-β pathway has been associated with the development of various diseases, including cancer, neurodegenerative disorders, and cardiovascular diseases.

TMEM42 has been shown to play a critical role in the regulation of the TGF-β pathway. It has been shown to interact with several TGF-β signaling proteins, including SMAD2, SMAD4, and TGF-β1. TMEM42 has been shown to regulate the activity of these proteins, which are involved in the regulation of cell growth, differentiation, and survival.

In addition to its involvement in the TGF-β pathway, TMEM42 has also been shown to play a role in the regulation of various cellular processes, including cell adhesion, migration, and the regulation of ion channels. These processes are critical for the development and maintenance of various tissues and organs, including the brain, heart, and blood vessels.

Biomarker Potential

TMEM42 has also been identified as a potential biomarker for various diseases, including cancer. Its involvement in the TGF-β pathway has been shown to be associated with the development of various types of cancer, including breast, ovarian, and colorectal cancers. This suggests that TMEM42 may be a useful biomarker for the detection and diagnosis of these diseases.

Expression and Modulation

TMEM42 is highly expressed in various tissues and cells, including cancer cells. Its expression is regulated by various factors, including DNA methylation, histone modifications, and signaling pathways. For example, TMEM42 has been shown to be regulated by the p53 gene, which is a well-established regulator of the TGF-β pathway.

TMEM42 has also been shown to be regulated by various signaling pathways, including TGF-β signaling pathway. This is supported by the fact that TMEM42 has been shown to interact with several TGF-β signaling proteins, including SMAD2, SMAD4, and TGF-β1. These interactions suggest that TMEM42 may play a role in the regulation of TGF-β signaling pathway.

Conclusion

In conclusion, TMEM42 is a transmembrane protein that has been shown to play a critical role in the regulation of various cellular processes, including the TGF-β pathway. Its involvement in this pathway makes it a potential drug target for the development of various diseases, including cancer. The expression and regulation of TMEM42 have also been shown to be regulated by various factors, including DNA methylation and signaling pathways. Further research is needed to fully understand the role of TMEM42 in these processes and its potential as a drug target and biomarker.

Protein Name: Transmembrane Protein 42

The "TMEM42 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about TMEM42 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets